Doxycycline

Generic Name: Doxycycline

Brand Names: Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄N_₂O_₈

CAS Number: 564-25-0

Unique Ingredient Identifier: 334895S862

Background: Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.

Indication: Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:

It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions: Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection

Clinical Trials

Retrospective Study for Identificatiopn of a Link Between Doxycycline and COVID-19 Treatment

Withdrawn

Conditions: COVID-19

First Posted Date: 2022-07-06

Last Posted Date: 2025-01-16

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 10000

Registration Number: NCT05445479

Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma

Phase 1

Conditions: Rhinoscleroma

Interventions: Drug: Doxycycline
Drug: Rifampin
Drug: Ciprofloxacin

First Posted Date: 2022-06-24

Last Posted Date: 2022-07-07

Lead Sponsor: Assiut University

Target Recruit Count: 45

Registration Number: NCT05431673

Subantimicrobial Doxycycline in Acne

Phase 4

Completed

Conditions: Acne Vulgaris
Pediatrics

Interventions: Drug: Doxycycline Hyclate

First Posted Date: 2022-06-01

Last Posted Date: 2023-04-03

Lead Sponsor: Michigan State University

Target Recruit Count: 22

Registration Number: NCT05399290

Locations: 🇺🇸
Messenger Dermatology Clinic, Lansing, Michigan, United States

Efficacy of Azithromycin Plus Doxycycline Versus Doxycycline Plus Placebo in Patients With Rocky Mountain Spotted Fever

Phase 3

Recruiting

Conditions: Rocky Mountain Spotted Fever

Interventions: Drug: Azithromycin + Doxycycline
Drug: Placebo + Doxycycline

First Posted Date: 2022-05-31

Last Posted Date: 2022-05-31

Lead Sponsor: Hospital General de Mexicali

Target Recruit Count: 86

Registration Number: NCT05398055

Locations: 🇲🇽
Hospital General de Mexicali, Mexicali, Baja California, Mexico

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

Phase 2

Recruiting

Conditions: Emphysema
HIV

Interventions: Drug: Placebo
Drug: Doxycycline

First Posted Date: 2022-05-19

Last Posted Date: 2024-06-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 250

Registration Number: NCT05382208

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Temple University, Philadelphia, Pennsylvania, United States
🇺🇸
University of California San Diego, San Diego, California, United States

and more 17 locations

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

Phase 3

Completed

Conditions: Papulopustular Rosacea

Interventions: Drug: DFD-29
Drug: Placebo
Drug: Doxycycline

First Posted Date: 2022-04-25

Last Posted Date: 2024-12-03

Lead Sponsor: Journey Medical Corporation

Target Recruit Count: 330

Registration Number: NCT05343455

Locations: 🇺🇸
Clinical Trial Site 14, Miami, Florida, United States
🇺🇸
Clinical Trial Site 05, Miramar, Florida, United States
🇺🇸
Clinical Trial Site 08, Clarksville, Indiana, United States

and more 21 locations

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

Phase 3

Completed

Conditions: Papulopustular Rosacea

Interventions: Drug: Doxycycline
Drug: DFD-29
Drug: Placebo

First Posted Date: 2022-03-25

Last Posted Date: 2024-12-03

Lead Sponsor: Journey Medical Corporation

Target Recruit Count: 323

Registration Number: NCT05296629

Locations: 🇺🇸
Clinical Trial Site 25, San Diego, California, United States
🇺🇸
Clinical Trial Site 13, Houston, Texas, United States
🇺🇸
Clinical Trial Site 02, Indianapolis, Indiana, United States

and more 24 locations